MedTrace Logo

The Effects of Neprilysin on Glucagon-like Peptide-1

NCT03717688 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2019-07-08

No results posted yet for this study

Summary

In the current study we wish to investigate the effects on glucagon-like peptide-1 (GLP-1) of a neprilysin inhibitor

Conditions

Interventions

DRUG

Entresto

Single dose administration of Entrestro 194 mg sacubitril / 206 mg valstartan

DRUG

Sitagliptin 100mg

2 x 100mg sitagliptin as single dose.

DRUG

Placebos

No treatment

Sponsors & Collaborators

  • Nicolai Jacob Wewer Albrechtsen

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-05-17
Primary Completion
2019-02-01
Completion
2019-05-14

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03717688 on ClinicalTrials.gov